<DOC>
	<DOC>NCT02986295</DOC>
	<brief_summary>Comparison of safety and long-term effects of BioMimeTM stent and Ultimaster® stent with Xience® stent</brief_summary>
	<brief_title>Real World Drug-Eluting Stent Prospective, Open, Multi-site, Registry in Korea: BioMimeTM Stent, Ultimaster® Stent vs. Xience® Stent By SMart Angioplastry Research Team (SMARTDESK-MX)</brief_title>
	<detailed_description>A prospective, open, multicenter, and observational study will register and compare Xience® groups treated in institutions such as the BioMime ™, Ultimaster® group prospectively registered from June 2016. The Xience® group has already been registered in the previous study (SMARTDESK-BX), so BioMimeTM and Ultimaster® only need to be registered. Follow-up will be conducted until December 2019, and e-CRF will be completed by April 2020.</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<criteria>1. 19 years old or older 2. Clinical evidence of coronary artery disease including asymptomatic ischemia, stable angina pectoris, acute coronary syndrome (unstable angina, nonST segment elevation myocardial infarction, ST segment elevation myocardial infarction). 3. Vessel diameter 2.25 ~ 3.5mm, stenosis more than 50% (However, the number of blood vessels, the number of lesions, and the lesion length are not limited) 4. Voluntary written consent to participate in the trial 1. Within 24 hours before percutaneous coronary intervention, hemodynamic instability or cardiogenic shock 2. Life expectancy within 2 years</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>BioMime, Ultimaster, Ischemic heart disease, DES</keyword>
</DOC>